Health Care • Biotechnology: Pharmaceutical Preparations
$21.31 ▲ +0.19
(+0.90%)
MKT CAP: $1.54B • VOL: 626.9K
52W L $18 52W H $25
ROARABLE / RQD
B • 75/100
PIOTROSKI
6 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$18
MEDIAN
$24
MEAN
$24
HIGH
$29
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE INVA TAPE
INVA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $25.79 | $24.51 | 2025-02-14 | $19.39 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $26.85 | $25.15 | 2025-02-06 | $20.03 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $24.29 | $23.44 | 2025-01-29 | $20.46 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $21.74 | — | 2025-01-17 | $20.88 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $18.75 | $20.24 | 2025-01-09 | $18.97 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $25.36 | $22.16 | 2024-12-18 | $18.54 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $20.67 | $21.52 | 2024-12-04 | $19.82 | -4.3% | 48% | C |